on December 8, 2003
Circulation. 2003
Published online before print December 8, 2003, doi: 10.1161/01.CIR.0000105764.22626.B1
Published online before print December 8, 2003, doi: 10.1161/01.CIR.0000105764.22626.B1
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 8, 2003
From the Department of Internal Medicine (J.T.K., B.I., S.S., M.M.H., H.H., D.F.) and the Institute of Clinical Pharmacology (D.T., J.C.F.), Medical School Hannover; and the Institute of Clinical Pharmacology, Otto-von-Guericke-University Magdeburg (S.M.B.-B.), Germany. * To whom correspondence should be addressed. E-mail: kielstein{at}yahoo.com.
Background--Increased blood concentrations of the endogenous nitric oxide synthase (NOS) inhibitor asymmetrical dimethylarginine (ADMA) have been linked to excess cardiovascular morbidity and mortality and to progression of renal disease. We evaluated systemic cardiovascular effects of ADMA infusion in healthy subjects using invasive techniques, ie, right heart catheter and inulin/para-aminohippurate clearance. Methods and Results--Plasma ADMA concentrations encountered in patients with cardiovascular diseases, ie, between 2 and 10 µmol/L, caused a significant (P<0.05) decrease in concentrations of plasma cGMP, the main second messenger of NO. In addition, cardiac output was significantly lower (5.3±0.4 versus 5.8±0.6 L/min; P<0.05 versus baseline), and systemic vascular resistance was significantly higher (1403±123 versus 1221±100 dyn · s · cm-5; P<0.05 versus baseline). The infusion of 0.25 mg ADMA · kg-1 · min-1 or 3 µg NG-nitro-L-arginine methyl ester · kg-1 · min-1, a potent synthetic NOS inhibitor with long action, resulted in a comparable decrease in effective renal plasma flow (from 670±40 to 596±29 mL · min-1; P<0.05) and an increase in renovascular resistance (from 79±5 to 90±7 mm Hg · mL-1 · min-1; P<0.05). Moreover, administration of ADMA caused significant sodium retention and blood pressure increase (both P<0.05). The observed effects of ADMA in the systemic circulation were sustained corresponding to a mean plasma half-life of 23.5±6.8 minutes, calculated from plasma ADMA decay curves in healthy subjects. Conclusions--Systemic ADMA infusion is responsible for a short-term, modest decrease in cardiac output with comparable decrease in effective renal plasma flow while increasing systemic vascular resistance and blood pressure in a dose-related manner.
Revised on September 23, 2003
Accepted on September 25, 2003
Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans
Jan T. Kielstein MD*,
Key words: nitric oxide synthase • vasculature • asymmetrical dimethylarginine
This article has been cited by other articles:
 |
|
 |
|
  M. Lajer, L. Tarnow, A. Jorsal, T. Teerlink, H.-H. Parving, and P. Rossing Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy Diabetes Care, April 1, 2008; 31(4): 747 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lucke, N. Kanzelmeyer, K. Chobanyan, D. Tsikas, D. Franke, M. J. Kemper, J. H.H. Ehrich, and A. M. Das Elevated asymmetric dimethylarginine (ADMA) and inverse correlation between circulating ADMA and glomerular filtration rate in children with sporadic focal segmental glomerulosclerosis (FSGS) Nephrol. Dial. Transplant., February 1, 2008; 23(2): 734 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vanholder, S. V. Laecke, F. Verbeke, G. Glorieux, and W. V. Biesen Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies NDT Plus, February 1, 2008; 1(1): 2 - 10. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Baylis Nitric oxide deficiency in chronic kidney disease Am J Physiol Renal Physiol, January 1, 2008; 294(1): F1 - F9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kjolby and P. Bie Chronic activation of plasma renin is log-linearly related to dietary sodium and eliminates natriuresis in response to a pulse change in total body sodium Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R17 - R25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Skoro-Sajer, F. Mittermayer, A. Panzenboeck, D. Bonderman, R. Sadushi, R. Hitsch, J. Jakowitsch, W. Klepetko, M. P. Kneussl, M. Wolzt, et al. Asymmetric Dimethylarginine Is Increased in Chronic Thromboembolic Pulmonary Hypertension Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1154 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vanholder, N. Meert, E. Schepers, G. Glorieux, A. Argiles, P. Brunet, G. Cohen, T. Drueke, H. Mischak, G. Spasovski, et al. Review on uraemic solutes II Variability in reported concentrations: causes and consequences Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3115 - 3121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Juonala, J. S.A. Viikari, G. Alfthan, J. Marniemi, M. Kahonen, L. Taittonen, T. Laitinen, and O. T. Raitakari Brachial Artery Flow-Mediated Dilation and Asymmetrical Dimethylarginine in the Cardiovascular Risk in Young Finns Study Circulation, September 18, 2007; 116(12): 1367 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, P. S. Gill, T. Chabrashvili, M. L. Onozato, J. Raggio, M. Mendonca, K. Dennehy, M. Li, P. Modlinger, J. Leiper, et al. Isoform-Specific Regulation by NG,NG-Dimethylarginine Dimethylaminohydrolase of Rat Serum Asymmetric Dimethylarginine and Vascular Endothelium-Derived Relaxing Factor/NO Circ. Res., September 14, 2007; 101(6): 627 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Kielstein, K. Sydow, and T. Thum Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock JAMA, September 5, 2007; 298(9): 971 - 971. [Full Text] [PDF]
|
|
|
|
|
|
T. Teerlink Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock JAMA, September 5, 2007; 298(9): 971 - 972. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Duckelmann, F. Mittermayer, D. G. Haider, J. Altenberger, J. Eichinger, and M. Wolzt Asymmetric Dimethylarginine Enhances Cardiovascular Risk Prediction in Patients With Chronic Heart Failure Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2037 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhao, Z. Liu, Z. Wang, C. Yang, J. Liu, and J. Lu Effect of Prepro-Calcitonin Gene-Related Peptide Expressing Endothelial Progenitor Cells on Pulmonary Hypertension Ann. Thorac. Surg., August 1, 2007; 84(2): 544 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Wilson, R. Harada, N. Nair, N. Balasubramanian, and J. P. Cooke L-Arginine Supplementation in Peripheral Arterial Disease: No Benefit and Possible Harm Circulation, July 10, 2007; 116(2): 188 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin, M. L. Lipman, and J. F.E. Mann Chronic Kidney Disease: Effects on the Cardiovascular System Circulation, July 3, 2007; 116(1): 85 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tsuda Asymmetric Dimethylarginine and Hypertension in Cerebral Small Vessel Disease Stroke, July 1, 2007; 38(7): e48 - e48. [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Kielstein and C. Zoccali A New Perspective for the Treatment of Renal Diseases? J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1365 - 1367. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Maas, F. Schulze, J. Baumert, H. Lowel, K. Hamraz, E. Schwedhelm, W. Koenig, and R. H. Boger Asymmetric Dimethylarginine, Smoking, and Risk of Coronary Heart Disease in Apparently Healthy Men: Prospective Analysis from the Population-Based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and Experimental Data Clin. Chem., April 1, 2007; 53(4): 693 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsuda Asymmetric Dimethylarginine and Cerebrovascular Disorders in Humans Stroke, December 1, 2006; 37(12): 2870 - 2870. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antoniades, D. Tousoulis, K. Marinou, C. Vasiliadou, C. Tentolouris, G. Bouras, C. Pitsavos, and C. Stefanadis Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 781 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Billecke, L. A. Kitzmiller, J. J. Northrup, S. E. Whitesall, M. Kimoto, A. V. Hinz, and L. G. D'Alecy Contribution of whole blood to the control of plasma asymmetrical dimethylarginine Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1788 - H1796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-Z. Zhang, K. Venardos, J. Chin-Dusting, and D. M. Kaye Response to Cigarettes and ADMA: The Smoke Hasn't Cleared Yet Hypertension, October 1, 2006; 48(4): E21 - E21. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Kielstein, J. P. Cooke, and C. Zoccali Letter by Kielstein et al Regarding Article, "Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure" Circulation, August 8, 2006; 114(6): e242 - e242. [Full Text] [PDF]
|
|
|
|
|
|
K. Matsuguma, S. Ueda, S.-i. Yamagishi, Y. Matsumoto, U. Kaneyuki, R. Shibata, T. Fujimura, H. Matsuoka, M. Kimoto, S. Kato, et al. Molecular Mechanism for Elevation of Asymmetric Dimethylarginine and Its Role for Hypertension in Chronic Kidney Disease J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2176 - 2183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Kielstein, F. Donnerstag, S. Gasper, J. Menne, A. Kielstein, J. Martens-Lobenhoffer, F. Scalera, J. P. Cooke, D. Fliser, and S. M. Bode-Boger ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in Humans Stroke, August 1, 2006; 37(8): 2024 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Menne, J.-K. Park, R. Agrawal, C. Lindschau, J. T. Kielstein, T. Kirsch, A. Marx, D. Muller, F. H. Bahlmann, M. Meier, et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers FASEB J, May 1, 2006; 20(7): 994 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Elesber, H. Solomon, R. J. Lennon, V. Mathew, A. Prasad, G. Pumper, R. E. Nelson, J. P. McConnell, L. O. Lerman, and A. Lerman Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis Eur. Heart J., April 1, 2006; 27(7): 824 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Carello, S. E. Whitesall, M. C. Lloyd, S. S. Billecke, and L. G. D'Alecy Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H209 - H216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fliser, F. Kronenberg, J. T. Kielstein, C. Morath, S. M. Bode-Boger, H. Haller, and E. Ritz Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2456 - 2461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ravani, G. Tripepi, F. Malberti, S. Testa, F. Mallamaci, and C. Zoccali Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease: A Competing Risks Modeling Approach J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2449 - 2455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vallance and J. Leiper Asymmetric Dimethylarginine and Kidney Disease--Marker or Mediator? J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2254 - 2256. [Full Text] [PDF]
|
|
|
|
|
|
E. Schwedhelm, J. Tan-Andresen, R. Maas, U. Riederer, F. Schulze, and R. H. Boger Liquid Chromatography-Tandem Mass Spectrometry Method for the Analysis of Asymmetric Dimethylarginine in Human Plasma Clin. Chem., July 1, 2005; 51(7): 1268 - 1271. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Kielstein, S. M. Bode-Boger, G. Hesse, J. Martens-Lobenhoffer, A. Takacs, D. Fliser, and M. M. Hoeper Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1414 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mittermayer, G. Schaller, J. Pleiner, A. Vychytil, G. Sunder-Plassmann, W. H. Horl, and M. Wolzt Asymmetrical Dimethylarginine Plasma Concentrations Are Related to Basal Nitric Oxide Release but Not Endothelium-Dependent Vasodilation of Resistance Arteries in Peritoneal Dialysis Patients J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1832 - 1838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H Boger Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials Vascular Medicine, May 1, 2005; 10(2_suppl): S19 - S25. [Abstract] [PDF]
|
|
|
|
|
|
K. Sydow, C. E Mondon, and J. P Cooke Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA Vascular Medicine, May 1, 2005; 10(2_suppl): S35 - S43. [Abstract] [PDF]
|
|
|
|
|
|
R. Maas Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA) Vascular Medicine, May 1, 2005; 10(2_suppl): S49 - S57. [Abstract] [PDF]
|
|
|
|
|
|
T. Thum and J. Bauersachs Spotlight on endothelial progenitor cell inhibitors: short review Vascular Medicine, May 1, 2005; 10(2_suppl): S59 - S64. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Puder, S. Nilavar, K. D. Post, and P. U. Freda Relationship between Disease-Related Morbidity and Biochemical Markers of Activity in Patients with Acromegaly J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1972 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ziegler, F. Mittermayer, C. Plank, E. Minar, M. Wolzt, and G.-H. Schernthaner Homocyst(e)ine-Lowering Therapy Does Not Affect Plasma Asymmetrical Dimethylarginine Concentrations in Patients with Peripheral Artery Disease J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2175 - 2178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fliser, K.-K. Wagner, A. Loos, D. Tsikas, and H. Haller Chronic Angiotensin II Receptor Blockade Reduces (Intra)Renal Vascular Resistance in Patients with Type 2 Diabetes J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1135 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Verhave, P. Fesler, G. du Cailar, J. Ribstein, M. E. Safar, and A. Mimran Elevated Pulse Pressure Is Associated With Low Renal Function in Elderly Patients With Isolated Systolic Hypertension Hypertension, April 1, 2005; 45(4): 586 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Devynck, A. Simon, M.-G. Pernollet, G. Chironi, J. Gariepy, F. Rendu, and J. Levenson Plasma cGMP and Large Artery Remodeling in Asymptomatic Men Hypertension, December 1, 2004; 44(6): 919 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bourraindeloup, C. Adamy, G. Candiani, M. Cailleret, M.-C. Bourin, T. Badoual, J. B. Su, S. Adubeiro, F. Roudot-Thoraval, J.-L. Dubois-Rande, et al. N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-{alpha} Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats Circulation, October 5, 2004; 110(14): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Gokce L-Arginine and Hypertension J. Nutr., October 1, 2004; 134(10): 2807S - 2811S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Boger Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the "L-Arginine Paradox" and Acts as a Novel Cardiovascular Risk Factor J. Nutr., October 1, 2004; 134(10): 2842S - 2847S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Achan, J. T. Kielstein, B. Impraim, S. Simmel, M. M. Hoeper, H. Haller, D. Fliser, D. Tsikas, J. C. Frolich, and S. M. Bode-Boger Cardiovascular Effects of Asymmetric Dimethylarginine * Response Circulation, June 29, 2004; 109(25): e327 - e327. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Blankestijn Sympathetic hyperactivity in chronic kidney disease Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1354 - 1357. [Full Text] [PDF]
|
|
|
|
|
|
P. Vallance and J. Leiper Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1023 - 1030. [Abstract] [Full Text] [PDF]
|
|